Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria~* Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at baseline~Exclusion Criteria:~* Primary progressive multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
- Ozanimod1 mg (Type: EXPERIMENTAL): Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
- Interferon β-1a (Type: ACTIVE_COMPARATOR): interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).